The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2015 | OS after adjustment for crossover in a study of idelalisib with rituximab for relapsed CLL
At the 20th Congress of the European Hematology Association (EHA), Paolo Ghia, MD, PhD, of Università Vita-Salute San Raffaele, Milan, Italy, discusses the overall survival (OS) analysis adjusting for treatment effect after crossover in a phase 3 study evaluating the PI3K delta inhibitor, idelalisib, in combination with rituximab in patients with relapsed chronic lymphocytic leukemia (CLL).
